Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

• Váldodahkkit: Abundio Balgos (Dahkki), Suad Hannawi (Dahkki), Wen-Li Chen (Dahkki), Alaa Abuquta (Dahkki), Linda Safeldin (Dahkki), Aala Hassan (Dahkki), Ahmad Alamadi (Dahkki), Louie Tirador (Dahkki), Anjuli May Jaen (Dahkki), Ralph Elvi Villalobos (Dahkki), Chen Mo (Dahkki), Zi-Jing Yue (Dahkki), Ying Ma (Dahkki), Qing-Shuang Wang (Dahkki), Ren-Du Wen (Dahkki), Zheng Yao (Dahkki), Jia-Ping Yu (Dahkki), Wen-Rong Yao (Dahkki), Jian-Hui Zhang (Dahkki), Kun-Xue Hong (Dahkki), Yong Liu (Dahkki), Jing-Xin Li (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ABSTRACTBackground Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.Research design and methods Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivate...